New Insight: A Look at OPT-302/Sozinibercept with Megan Baldwin, PhD

from HCPLive Podcasts · host HCPLive.com

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases.Episode Highlights:0:06 Introduction0:37 Background of Dr. Baldwin9:56 Promising data on OPT-302/sozinibercept16:39 Making decisions as a clinician, industry leader22:11 Future of the treatment landscape28:24 What’s next for Opthea?32:39 ConclusionPlease direct any podcast-related inquiries to [email protected].

Episode metadata supplied by the publisher feed · Published Sep 8, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

New Insight: A Look at OPT-302/Sozinibercept with Megan Baldwin, PhD

0:00 33:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of HCPLive Podcasts?

This episode is 33 minutes long.

When was this HCPLive Podcasts episode published?

This episode was published on September 8, 2023.

Can I download this HCPLive Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!